派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果

智通财经网03-06

智通财经APP讯，派格生物医药-B(02565)发布公告，公司基于环状RNA(CircRNA)蛋白替代技术并结合人工智能辅助分子设计平台自主研发的新一代GLP-1受体激动剂CR059，为PB-2309三受体(GLP-1/GIP/GCG)激动剂项目分阶段开发策略中针对GLP-1受体激动机制进行先行临床验证的候选产品，已于受试者中完成单次给药并取得一个月人体临床观察结果。CR059采用脂质纳米颗粒(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617685492?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-03-06 17:04","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2617685492","market":"hk","top_or_hot":-1,"title":"派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，派格生物医药-B(02565)发布公告，公司基于环状RNA(CircRNA)蛋白替代技术并结合人工智能辅助分子设计平台自主研发的新一代GLP-1受体激动剂CR059，为PB-2309三受体(GLP-1/GIP/GCG)激动剂项目分阶段开发策略中针对GLP-1受体激动机制进行先行临床验证的候选产品，已于受试者中完成单次给药并取得一个月人体临床观察结果。CR059采用脂质纳米颗粒(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410994.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-06 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410994.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，派格生物医药-B(02565)发布公告，公司基于环状RNA(CircRNA)蛋白替代技术并结合人工智能辅助分子设计平台自主研发的新一代GLP-1受体激动剂CR059，为PB-2309三受体(GLP-1/GIP/GCG)激动剂项目分阶段开发策略中针对GLP-1受体激动机制进行先行临床验证的候选产品，已于受试者中完成单次给药并取得一个月人体临床观察结果。CR059采用脂质纳米颗粒(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410994.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"399441","symbol_name":"生物医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410994.html","article_id":"2617685492","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617685492","pubTimestamp":1772787852,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"派格生物医药-B(02565)发布公告，公司基于环状RNA(CircRNA)蛋白替代技术并结合人工智能辅助分子设计平台自主研发的新一代GLP-1受体激动剂CR059，为PB-2309三受体(GLP-1/GIP/GCG)激动剂项目分阶段开发策略中针对GLP-1受体激动机制进行先行临床验证的候选产品，已于受试者中完成单次给药并取得一个月人体临床观察结果。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","GLP":"Global Partners Lp","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4590":"PTP","02565":"派格生物医药-B","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4144":"石油与天然气的储存和运输"},"translate_title":"Paige Biomedical-B (02565): The first human trial of Paige Biologics' new generation GLP-1 (CR059) achieved one-month clinical observation results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"LABU":1.5,"02565":1.5,"GLP":1.5},"content_text":"智通财经APP讯，派格生物医药-B(02565)发布公告，公司基于环状RNA(CircRNA)蛋白替代技术并结合人工智能辅助分子设计平台自主研发的新一代GLP-1受体激动剂CR059，为PB-2309三受体(GLP-1/GIP/GCG)激动剂项目分阶段开发策略中针对GLP-1受体激动机制进行先行临床验证的候选产品，已于受试者中完成单次给药并取得一个月人体临床观察结果。CR059采用脂质纳米颗粒(LNP)递送系统，通过体内持续表达GLP-1受体激动剂以实现长效代谢干预，预期有助于延长给药间隔并提升患者治疗依从性。在db/db小鼠模型中，于以司美格鲁肽作为对照的头对头研究条件下，CR059呈现更强的代谢干预效应并显示明确的剂量-反应关系，支持其基于体内表达机制实现稳定GLP-1受体激动效应。在自发性2型糖尿病恒河猴模型中，CR059每月一次皮下注射(D1、D32)给药后可显著降低空腹血糖，且代谢改善效应可跨越给药间隔持续存在;至D88糖化血红蛋白(HbA1c)较基线持续改善，显示基于环状RNA的体内蛋白持续表达策略有潜力支持延长给药间隔的治疗模式。在健康恒河猴模型中，CR059单次皮下注射后可在数周内维持代谢干预效应(单次给药后5周体重下降约11.8%)，进一步支持低频给药策略，并为慢性代谢疾病由反复外源给药向持续体内表达转变提供证据。目前，公司正在开展一项评估CR059于2型糖尿病(T2DM)受试者中的安全性、耐受性及药代动力学╱药效学(PK/PD)特征的首次人体临床研究。本次FIH研究除旨在评估CR059单一产品的安全性与初步有效性外，亦用于探索基于环状RNA的蛋白替代技术于慢性代谢疾病中实现持续体内表达及低频给药策略的临床可行性。在单次给药后四周临床观察到：糖化血红蛋白(HbA1c)及空腹血糖较基线持续改善;连续血糖监测(CGM)显示血糖控制于目标区间(4-10mmol/L)的时间比例(TIR)提升，反映整体血糖控制状况改善;及平均血糖水平显著下降。人体研究结果显示，CR059单次给药后仍可观察到持续代谢改善趋势，支持基于环状RNA的持续体内表达策略于慢性代谢疾病中实现低频给药，并为长期系统治疗模式提供人体层面的可行性信号。本次人体初步观察结果亦显示，基于环状RNA的体内蛋白持续表达策略或具备支持慢性代谢疾病长期系统干预的潜力。公司的环状RNA平台通过优化密码子结构设计实现高效成环，避免外源连接酶或化学修饰的引入，并结合高表达IRES元件与翻译增强序列，使环状RNA在无5’cap与poly(A)尾条件下仍可实现稳定且持续的蛋白翻译。上述设计有助于延长治疗性蛋白于体内的有效表达时间，从而支持由反复外源给药向持续体内表达转变的蛋白替代治疗策略，并为慢性代谢疾病等需长期系统干预的适应症提供低频给药的技术路径。该技术路径有望为慢性疾病由反复外源给药向持续体内表达转变提供新的治疗模式。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617685492","isCrawlerRequest":true}